Xcout Intel
Astellas Pharma competitors & alternatives
The 12 closest competitors and alternatives to Astellas Pharma among pharmaceuticals companies — ranked by similarity to what Astellas Pharma actually does, not by market-cap band.
Subscribe to see Astellas Pharma’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Astellas Pharma
Astellas Pharma Inc. is a Japanese pharmaceutical company headquartered in Tokyo. The company has global offices and research centers.
Astellas Pharma at a glance
Astellas Pharma is a pharmaceuticals company headquartered in Japan, founded in 2005. Xcout tracks 15 named people at Astellas Pharma, including Naoki Okamura (Representative Director, President and Chief Executive Officer (CEO)). Xcout recorded 2 job postings from Astellas Pharma in the last 90 days.
Astellas Pharma leadership
- Naoki OkamuraRepresentative Director, President and Chief Executive Officer (CEO)
- Atsushi KitamuraChief Financial Officer (CFO)
- Katsuyoshi SugitaRepresentative Director, Executive Vice President, Chief People Officer (CPO)
- Claus ZielerChief Commercial & Medical Affairs Officer (CCMAO)
- Rao Mantri, Ph.D.Chief Manufacturing Officer (CMfgO)
- Tadaaki Taniguchi, M.D., Ph.D.Chief Research & Development Officer (CRDO)
9 more named people on record for Astellas Pharma, with roles, board committees and tenure — see the full roster →
Hiring at Astellas Pharma
Xcout recorded 2 job postings from Astellas Pharma in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Astellas Pharma's hiring signals →
Top 12 Astellas Pharma competitors
Ranked by semantic similarity — how close each company is to Astellas Pharma by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals company
Fuji Pharma Co., Ltd. is a pharmaceutical company that operates globally, focusing on the complete spectrum of drug development, from initial research and discovery through manufacturing and commercialization. Its comprehensive product line includes various medical solutions such as injectable medications, oral therapeutics, topical treatments, and a range of diagnostic tools. Beyond its core pharmaceutical offerings, Fuji Pharma also specializes in women's healthcare products, advanced in vitro diagnostic technologies, and acute medical intervention solutions. The company further contributes by disseminating valuable pharmaceutical and general health information. Founded in 1965, Fuji Pharma Co., Ltd. has its corporate headquarters located in Tokyo, Japan.
Similar pharmaceuticals company
Santen Pharmaceutical Co., Ltd. is headquartered in Osaka, Japan, and is a global leader in ophthalmological research, development, production, and marketing of related pharmaceuticals and medical devices.
Similar pharmaceuticals company
Otsuka Pharmaceutical Co., Ltd., abbreviated OPC, is a pharmaceutical company headquartered in Chiyoda, Tokyo, Japan. The company's philosophy is "Otsuka-people creating new products for better health worldwide."
Similar pharmaceuticals company
Sumitomo Pharma Company Limited is a Japanese multinational pharmaceutical company. The company is focused on oncology, psychiatry, neurology, women's health issues, urological diseases among other areas. Its headquarters are located in Chuo-ku, Osaka.
Similar pharmaceuticals company
Daiichi Sankyo Co., Ltd. is a global pharmaceutical company with a strong legacy of innovation. The company maintains a robust pipeline of medicines and has a presence in various countries, including Canada and the US.
Similar pharmaceuticals company
Taiho Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company, and a subsidiary of Otsuka Holdings, which focuses on developing cancer treatments. Taiho, headquartered in Tokyo, Japan, is an R&D-driven specialty pharma focusing on the three fields of oncology, allergies and immunology, and urology.
Similar pharmaceuticals company
Eisai U.S. is a human-centered pharmaceutical company focused on driving medical innovation through research, development, and manufacturing.
Similar pharmaceuticals company
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.
Similar pharmaceuticals company
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
Similar pharmaceuticals company
Otsuka America Pharmaceutical, Inc. is a healthcare and pharmaceutical company headquartered in Princeton, New Jersey, operating within the United States.
Similar pharmaceuticals company
Ono Pharmaceutical Co., Ltd., along with its affiliated companies, is engaged in the global development, manufacturing, procurement, and sale of a diverse range of pharmaceutical products and diagnostic tools. Its diverse oncology portfolio includes OPDIVO intravenous infusions, KYPROLIS for injection, MEKTOVI, VELEXBRU, and ADLUMIZ tablets, along with BRAFTOVI capsules, all prescribed for various malignant tumors. It also provides EMEND capsules and PROEMEND intravenous injections to alleviate chemotherapy-induced nausea and vomiting, and DEMSER capsules for managing symptoms in pheochromocytoma patients. Beyond oncology, the company's offerings span multiple therapeutic areas. For metabolic disorders, it supplies GLACTIV and FORXIGA tablets for type 2 diabetes. Cardiovascular health is supported by ONOACT injections for tachyarrhythmia, CORALAN for chronic heart failure, and OPALMON tablets addressing peripheral circulatory disorders. Autoimmune conditions like rheumatoid arthritis are treated with ORENCIA injections. Neurological therapies include RIVASTACH patches for Alzheimer's disease and ONGENTYS tablets for Parkinson's disease. Other notable products are PARSABIV intravenous injections for dialysis patients, STAYBLA tablets for overactive bladder, ONON capsules and dry syrups for bronchial asthma and allergic rhinitis, and RECALBON tablets for osteoporosis, with JOYCLU intra-articular injection available to improve joint function. Moreover, the company is heavily invested in research and development, with a pipeline targeting a wide array of diseases. This includes various malignancies such as esophageal, urothelial, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular, pancreatic, biliary tract, gastric, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, and virus-positive/negative solid tumors, as well as primary central nervous system lymphoma. Beyond cancer, its developmental efforts extend to myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative and autoimmune disorders, narcolepsy, and thrombosis. Established in 1717, the company maintains its corporate headquarters in Osaka, Japan.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Astellas Pharma and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Astellas Pharmaand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →